S100A9 and psoriasis: Adalimumab, etanercept, and ustekinumab exert a protective effect in psoriasis via reducing the S100A7 and S100A8/S100A9 drastically in skin samples as indicated by immunohistochemistry (D'Amico et al., 2018[28], 2015[29]).